Ge Long Hui·2025-12-08 20:08Core Viewpoint - Lijun Group (000513.SZ) announced that it has 194 products included in the National Medical Insurance Directory for 2025, which is expected to positively impact the company's operating performance in the future [1] Group 1: Product Inclusion - The group has 194 products in the National Medical Insurance Directory, including 92 Class A and 102 Class B products [1] - Injectable Aripiprazole microspheres have been included in the National Medical Insurance Directory for the first time through negotiations [1] - Injectable Triptorelin acetate microspheres have a new indication added, and Injectable Esomeprazole sodium has successfully renewed its contract [1] - No products from the group have exited the National Medical Insurance Directory [1] Group 2: Market Impact - The inclusion of these products in the National Medical Insurance Directory is expected to help expand the market and improve drug accessibility [1] - The new version of the National Medical Insurance Directory will be officially implemented on January 1, 2026, and is not expected to have a significant impact on the company's current operating performance [1]